Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Journal of Clinical Pharmacology
|
October 30, 2014
Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers
David Joseph, Peter Rose, Natalja Strelkowa, et al.
ERJ Open Research
|
October 27, 2022
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
Toby M Maher, Christina Schlecker, Doreen Luedtke, et al.
Clinical Pharmacology in Drug Development
|
June 8, 2018
Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers
Friederike Kanefendt, Uwe Thuß, Michael Becka, et al.
Clinical Pharmacology in Drug Development
|
August 31, 2021
Pharmacokinetics, Safety, and Tolerability of the α<sub>2C</sub> -Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects
Stefanie Kapsa, Uwe Thuss, Stefanie Boxnick, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
February 3, 2025
Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers
Friedrich Schulze, Jennifer Schaible, Markus Goettel, et al.
Clinical Pharmacology in Drug Development
|
April 29, 2016
A Thorough QT Study of Teduglutide in Healthy Subjects
Manfred Hartmann, Wolfgang Timmer, Armin Schultz, et al.
Clinical Drug Investigation
|
September 26, 2019
Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects
Dénes Csonka, Shirin Bruderer, Armin Schultz, et al.
Clinical Pharmacology in Drug Development
|
October 20, 2022
Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant
Timothy Tyler, Armin Schultz, Alessio Venturini, et al.
British Journal of Clinical Pharmacology
|
May 7, 2020
Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects
Simon Grill, Shirin Bruderer, Patricia N Sidharta, et al.
Physiological Reviews
|
July 5, 2003
Nongenomic steroid action: controversies, questions, and answers
Ralf M Losel, Elisabeth Falkenstein, Martin Feuring, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Journal of Clinical Pharmacology
|
October 30, 2014
Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers
David Joseph, Peter Rose, Natalja Strelkowa, et al.
ERJ Open Research
|
October 27, 2022
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
Toby M Maher, Christina Schlecker, Doreen Luedtke, et al.
Clinical Pharmacology in Drug Development
|
June 8, 2018
Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers
Friederike Kanefendt, Uwe Thuß, Michael Becka, et al.
Clinical Pharmacology in Drug Development
|
August 31, 2021
Pharmacokinetics, Safety, and Tolerability of the α<sub>2C</sub> -Adrenoreceptor Antagonist BAY 1193397 in Healthy Male Subjects
Stefanie Kapsa, Uwe Thuss, Stefanie Boxnick, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology
|
February 3, 2025
Phase 1 studies of the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 690517 (vicadrostat), a novel aldosterone synthase inhibitor, in healthy male volunteers
Friedrich Schulze, Jennifer Schaible, Markus Goettel, et al.
Clinical Pharmacology in Drug Development
|
April 29, 2016
A Thorough QT Study of Teduglutide in Healthy Subjects
Manfred Hartmann, Wolfgang Timmer, Armin Schultz, et al.
Clinical Drug Investigation
|
September 26, 2019
Effect of Macitentan on the Pharmacokinetics of the Breast Cancer Resistance Protein Substrates, Rosuvastatin and Riociguat, in Healthy Male Subjects
Dénes Csonka, Shirin Bruderer, Armin Schultz, et al.
Clinical Pharmacology in Drug Development
|
October 20, 2022
Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant
Timothy Tyler, Armin Schultz, Alessio Venturini, et al.
British Journal of Clinical Pharmacology
|
May 7, 2020
Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects
Simon Grill, Shirin Bruderer, Patricia N Sidharta, et al.
Physiological Reviews
|
July 5, 2003
Nongenomic steroid action: controversies, questions, and answers
Ralf M Losel, Elisabeth Falkenstein, Martin Feuring, et al.
Page
of 3